ABVC BioPharma Sustains Profitable Global Licensing Deals and a Promising CDMO Acquisition, Enhancing Growth Prospects

• ABVC BioPharma expects approximately $19 million in cash revenue in 2025 from three global licensing agreements in psychiatric disorders, ophthalmic medical devices, and oncology.

• The company’s $60 million acquisition of a Contract Development and Manufacturing Organization (CDMO)strengthens its in-house manufacturing and contract manufacturing services.

ABVC BioPharma, a clinical-stage biopharmaceutical company, has provided an update on its expected cash milestone payments and CDMO investment. The company forecasts $19 million in licensing revenue in 2025, driven by three global licensing agreements. Additionally, ABVC’s $60 million CDMO acquisition reinforces its position in drug development and manufacturing.

Since 2023, ABVC has signed three global licensing deals with a total potential value of $959 million. These agreements cover drug candidates for major depressive disorder (MDD) and ADHD, an ophthalmic medical device (Vitargus®) for retinal detachment surgery, and an oncology drug targeting multiple cancers. These deals include upfront payments, milestone-based revenue, and commercialization royalties, contributing to the company’s long-term financial strategy.

ABVC’s acquisition of a CDMO in 2019 enhances its ability to manufacture pharmaceuticals in-house. The facility supports cost reduction, operational efficiency, and revenue diversification through contract manufacturing services for third-party companies. The CDMO sector is projected to reach $191 billion by 2029, positioning ABVC to benefit from rising demand for outsourcing pharmaceutical manufacturing.

“With these licensing agreements and our CDMO facility, we are well-positioned to generate revenue and expand our commercial footprint,” the company stated in its update.

Looking ahead, ABVC aims to strengthen its commercialization efforts and maximize value across its pipeline. The company anticipates that its integrated approach—combining licensing revenue and manufacturing capabilities—will drive long-term growth in the global pharmaceutical and medical device sectors.